www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on Management's transactions with ALK-Abelló A/S B shares and associated securities

March 23, 2017

PDF Version

Supporting Materials:
FM_12_17UK_23032017.pdf

 

 

Copenhagen, 2017-03-23 15:02 CET (GLOBE NEWSWIRE) --  

(ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions under securities identification code (ISIN) DK0060027142 / LEI code: 529900SGCREUZCZ7P020. The announcement is based on the allotments of share options and performance shares which ALK has granted to the Company's Board of Management on 23 March 2017 in accordance with the incentive pay guidelines adopted at the Company's annual general meeting on 15 March 2017:

 
Name
 
Position
 
Transaction
 
Number
Market value DKK 1,000
Carsten HellmannPresident & CEOAllotted share options4,880 
  Allotted performance shares985 
Total   1,875

  

 
Name
 
Position
 
Transaction
 
Number
Market value DKK 1,000
Henrik JacobiMember of Board
of Management
Allotted share options2,718 
  Allotted performance shares549 
Total   1,045

   

 
Name
 
Position
 
Transaction
 
Number
Market value, DKK 1,000
Søren NiegelMember of Board
of Management
Allotted share options 
2,624
 
  Allotted performance shares530 
Total   1,008

   

 
Name
 
Position
 
Transaction
 
Number
Market value DKK 1,000
Flemming
Pedersen
Member of Board
of Management
Allotted share options 
2,728
 
  Allotted performance shares550 
Total   1,048

   

 
Name
 
Position
 
Transaction
 
Number
Market value, DKK 1,000
Helle SkovMember of Board
of Management
Allotted share options 
2,603
 
  Allotted performance shares525 
Total   1,000

   

The shares are traded at NASDAQ Copenhagen. 

ALK-Abelló A/S
 

Steen Riisgaard
Chairman
 

For further information, please contact Steen Riisgaard, Chairman of the Board, tel. +45 4574 7576.

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved